Skip to content

New Features

New Features

As Arfinn Med has become the leading Electronic Medical Record (EMR) and practice management solution for medical cannabis clinics, we have continued to release new features to help improve clinical workflows and patient care. Our newest feature is a custom intake form builder to help gather pertinent patient information prior to appointments.

INTAKE FORM BUILDER

Arfinn Med allows users to add additional fields to their intake form to capture more patient information.  This can be done by hovering over the settings tab on your Dashboard and selecting the ‘Form Builder’ option. 

Once in the form builder interface, providers can select from different question types and drag and drop them into place.  Questions can be edited and made optional or required.  We also allow providers to code answers with different values to provide additional insight. Once all questions have been completed, click the save button. The custom form questions will now be viewable at the bottom of the existing intake form.   

In addition to the form builder, Arfinn Med has also released an expanded telehealth solution, more payment integrations, and a streamlined booking widget to help patients easily schedule appointments.

Learn more by scheduling a quick demo!

Stories you may be interested in

Medical marijuana helped elderly with chronic pain and reduced their use of opioids, study found

Your grandparents’ chronic aches and pains might best be eased with a little weed, a new study suggests. Not only did folks over 75 who took medical marijuana report less pain, their use of pot-based capsules, tinctures and e-cigarettes allowed a third of these patients to reduce their use of opioid painkillers, researchers found. “Medical marijuana, in…
Read More

Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders

Report of the Guideline Development Subcommittee of the American Academy of Neurology:   We performed a systematic review of medical marijuana (1948–November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We graded the studies according to the American Academy of Neurology classification scheme for therapeutic articles. Read the full…
Read More

Texas House Bill 3703: What You Need to Know

The state of Texas has been in the news in recent months as the legislature review House Bill 3703. This bill relates to “the prescription of low-THC cannabis for medical use by certain qualified physicians to patients with [specific] qualifying conditions”. Originally filed in March of 2019, this bill made its way through the house…
Read More

How Medical Marijuana Affects Men vs. Women

As expected, men and women differ in a multitude of ways, from genetic makeup and hormonal behavior to how we process information and emotionally respond. The differences in our makeup are the exact reason why any medical treatment, including medical marijuana, will have a diverse impact on men vs. women. Let’s take a closer look…
Read More

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More

Illinois dispensary to allow patients to substitute medical marijuana for opioids prescription

SPRINGFIELD, ILL. (KMOV.com) — Thursday, Illinois will become the first state to launch a revised medical marijuana program. The program allows pain suffers who use opioids to temporarily switch to medical marijuana. Following months of planning, the new initiative will launch at the HCI Alternatives medical cannabis dispensary in Springfield, Illinois. In a press release,…
Read More

Leave a Comment

You must be logged in to post a comment.